Navigation Links
Patent awarded for method to dampen immune response
Date:1/18/2011

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants. This therapeutic approach has the potential advantage of inactivating B cells instead of killing them as current treatments do. Therefore, this potential therapy could be more rapidly adjusted in response to the changing needs of patients.

B cells are a crucial part of the adaptive immune response, responsible for making antibodies that can neutralize and destroy pathogens. Several diseases, however, are associated with malfunction of B cells. For example, B cells can turn cancerous in diseases such as lymphoma and leukemia. In autoimmune diseases, such as rheumatoid arthritis or lupus, B cells turn against their own bodies and attack their tissues. B cells can also attack transplanted organs, which they recognize as foreign and potentially harmful.

The recently issued patent describes a method to inactivate B cells by disassembling their B-cell receptors. B cells begin producing antibodies after their B-cell receptors encounter foreign protein fragments, known as antigens. The B-cell receptor contains two distinct subunits; a receptor, which engages antigens, and a transducer, which transmits an activating signal to the interior of the cell.

About a decade ago, Dr. Cambier's laboratory, discovered that the two subunits could be separated, which disables the B cell's ability to recognize antigens and produce antibodies. In 2003, National Jewish Health received a patent (#6,503,509) for this method of B -cell desensitization. The most recent patent (#7,825,224) related to this technology claims the use of antibodies that bind to the transducer subunit of the receptor to inactivate the B cell.

Dr. Cambier's laboratory has recently developed several antibodies against one of the transducer elements, CD79, that have already yielded promising results.

"In contrast to current therapies for B-cell diseases, this method does not kill B cells, it merely inactivates them," said Dr. Cambier. "That could potentially allow for greater flexibility in using a therapy that is developed with this technology. Instead of the months to years it sometimes takes for the effects of current therapy to wane, our method could be reversed within days."

Dr. Cambier has recently received research funding from the State of Colorado and National Jewish Health through the Bioscience Discovery Evaluation Grant Program to further develop this promising technology.

"This research funding underlines our commitment to promote the translation of our scientists' research findings into therapeutic or diagnostic products that can ultimately help patients worldwide," said Emmanuel Hilaire, PhD, Manager of the Technology Transfer Office at National Jewish Health. "National Jewish is currently exploring various commercialization venues for its licensing, including the creation of a start-up company in Colorado."


'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Related medicine news :

1. National Jewish Health receives patent for diagnostic method of autoimmune chronic urticaria
2. National Jewish Health receives patent for liposome-based vaccine
3. K-State receives patent for noncontroversial source of stem cells
4. 15 new US patents awarded this past year to NJIT researchers
5. UR discovers new way to boost vaccines, seeks patent
6. Brookhaven Lab and BioSET Inc. patent improved growth factor technology
7. USF receives patent for technology to improve treatment for neurodegenerative diseases
8. Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
9. Greenway Awarded U.S. Patent For EHR Functionality and Workflow
10. Volumetrics Medical Imaging, LLC and Medison Co., Ltd. Announce Technology License and Settlement of Patent Litigation
11. Mobile and Patented: DATA-TO-CAMERA TOGGLE on handheld device replaces old camera and clipboard approach everywhere! Beats IPAD to camera punch too.....
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... VEGAS, NEV. (PRWEB) , ... August 22, 2017 ... ... American Academy of Anti-Aging Medicine recently spoke at a popular international aesthetics conference ... therapy has had on restoring his patients’ health and his growing practice. , ...
(Date:8/22/2017)... ... ... past six years, Lightning Labels has sent out a call for users of its custom ... creativity of their designs. Submissions this year were open from May 18 to July 1 ... winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... 2017 , ... Nurses at Apple Rehab Watch Hill , a nursing ... and certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... Centers for Medicare and Medicaid Services, to have a CPI machine that will provide ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a captivating and ... named Edward Koontz. “To Walk Away” is the creation of published author, Larry R. ... two hundred manuscripts in chemistry and religion, as well as four novels. , ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... heart-wrenching story of child abuse and neglect, and the struggles faced while hoping ... is the creation of published author, Judy Von Bernewitz, who spent 13 years ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... OCEANSIDE, Calif. , Aug. 15, 2017  AOTI Inc. announced ... Advanced Oxygen Therapy Inc., has recently opened a New York City ... the ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ... approved by the Accreditation Commission for Health Care (ACHC) under the ... ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
(Date:8/7/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO ... as president, effective Aug. 7, 2017. ... pursue other interests and will serve as president emeritus during ... served us in multiple leadership roles since he joined Diplomat ... and has provided decisive, strategic leadership which continues to benefit ...
Breaking Medicine Technology: